MaxCyte (MXCT) Competitors $1.39 -0.01 (-0.71%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.72%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MXCT vs. RPAY, RMR, NXTT, NUTX, DDI, SOHU, GRVY, ANPA, ABSI, and IMXIShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Repay (RPAY), The RMR Group (RMR), Next Technology (NXTT), Nutex Health (NUTX), DoubleDown Interactive (DDI), Sohu.com (SOHU), GRAVITY (GRVY), Rich Sparkle (ANPA), Absci (ABSI), and International Money Express (IMXI). These companies are all part of the "business services" industry. MaxCyte vs. Its Competitors Repay The RMR Group Next Technology Nutex Health DoubleDown Interactive Sohu.com GRAVITY Rich Sparkle Absci International Money Express Repay (NASDAQ:RPAY) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is RPAY or MXCT more profitable? Repay has a net margin of -35.79% compared to MaxCyte's net margin of -125.22%. Repay's return on equity of 8.89% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets Repay-35.79% 8.89% 4.31% MaxCyte -125.22%-22.12%-19.10% Do institutionals & insiders believe in RPAY or MXCT? 82.7% of Repay shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 12.0% of Repay shares are owned by insiders. Comparatively, 3.3% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, RPAY or MXCT? Repay has higher revenue and earnings than MaxCyte. Repay is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepay$310.37M1.75-$10.16M-$1.26-4.71MaxCyte$38.63M3.84-$41.06M-$0.43-3.23 Which has more risk and volatility, RPAY or MXCT? Repay has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Does the media prefer RPAY or MXCT? In the previous week, Repay had 8 more articles in the media than MaxCyte. MarketBeat recorded 11 mentions for Repay and 3 mentions for MaxCyte. Repay's average media sentiment score of 1.11 beat MaxCyte's score of 0.90 indicating that Repay is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repay 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MaxCyte 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RPAY or MXCT? Repay currently has a consensus price target of $7.22, indicating a potential upside of 21.59%. MaxCyte has a consensus price target of $7.00, indicating a potential upside of 403.60%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Repay.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repay 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44MaxCyte 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryRepay beats MaxCyte on 11 of the 16 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.25M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-3.2321.0831.2626.59Price / Sales3.84364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book0.788.0910.046.68Net Income-$41.06M-$54.08M$3.27B$265.59M7 Day Performance-2.11%2.25%3.17%3.42%1 Month Performance-38.50%3.41%4.34%1.09%1 Year Performance-67.22%18.61%44.12%23.84% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte3.1844 of 5 stars$1.39-0.7%$7.00+403.6%-67.0%$149.25M$38.63M-3.2380RPAYRepay3.6337 of 5 stars$5.53+1.8%$7.22+30.6%-30.1%$539.96M$313.04M-4.39580RMRThe RMR Group3.0239 of 5 stars$16.30-1.9%$24.00+47.2%-33.7%$529.48M$753.17M13.93600Positive NewsNXTTNext Technology1.4065 of 5 stars$1.12-1.8%N/A-62.0%$520.14M$1.80M0.008Positive NewsGap UpHigh Trading VolumeNUTXNutex Health2.9059 of 5 stars$94.55+1.8%$262.50+177.6%+281.9%$516.13M$479.95M7.951,150Analyst ForecastDDIDoubleDown Interactive4.0586 of 5 stars$9.47flat$19.25+103.3%-33.5%$469.27M$341.33M4.40220Positive NewsSOHUSohu.com3.3697 of 5 stars$15.30-1.7%$20.00+30.7%+2.3%$468.11M$594.65M3.674,300Trending NewsGRVYGRAVITY1.102 of 5 stars$65.07-1.6%N/A+1.4%$459.74M$566.30B7.80340News CoverageANPARich SparkleN/A$34.50-5.5%N/AN/A$456.25MN/A0.00N/ANews CoveragePositive NewsGap DownABSIAbsci2.8454 of 5 stars$2.83-3.4%$7.98+181.9%-43.2%$438.10M$4.53M-3.01210IMXIInternational Money Express3.069 of 5 stars$14.44+0.1%$19.60+35.7%-18.7%$428.04M$658.65M8.801,303News CoveragePositive NewsAnalyst Downgrade Related Companies and Tools Related Companies Repay Alternatives The RMR Group Alternatives Next Technology Alternatives Nutex Health Alternatives DoubleDown Interactive Alternatives Sohu.com Alternatives GRAVITY Alternatives Rich Sparkle Alternatives Absci Alternatives International Money Express Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MXCT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access